“…the γ‐site) as has been observed for the APP [21,23]. This alteration is detectable as an endophenotype of p3‐Alcα with C‐terminal variants in patients with AD [22] and in cells treated with compounds that modulate γ‐secretase activity [24,25]. These lines of evidence suggest that the function and metabolism of Alcs are also closely involved in AD pathobiology.…”